Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) Stock Analysis & Winston Score

Recordati is an Italian pharmaceutical company that makes and sells prescription medicines across Europe and beyond. Its main focus areas include rare diseases, where it sells treatments for uncommon genetic and metabolic conditions, as well as medicines for more common problems like high blood pressure, urological disorders, and mental health conditions. It is one of the largest independent pharmaceutical companies headquartered in Italy. Recordati earns money by selling branded prescription drugs to hospitals, pharmacies, and healthcare systems, primarily across Europe, the Middle East, and Africa. The company generates strong margins — over 70% gross margin — partly because its rare disease drugs face little competition and often carry premium pricing. Recordati was taken private by the CVC Capital Partners-led consortium in 2018 and later relisted, giving it a focused ownership structure. The key growth driver is expanding its rare disease portfolio, but the main risk is patent expirations and pricing pressure from European governments seeking to control healthcare costs.